Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.
Psychiatry November 7th 2023
Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.
Neurology October 3rd 2023
Psychiatrist.com
Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.
Psychiatry August 30th 2023
The newly released guidelines for psychedelic-assisted therapy by APPA and BrainFutures provide a comprehensive framework for mental health professionals. Explore the guidelines to understand the benchmarks for safety, ethics, and best practices in this emerging field.
Psychiatry August 15th 2023
Recent phase 3 clinical trials have demonstrated the eye-opening potential of MDMA in the treatment of PTSD when paired with psychotherapy, providing a new method of patient care.
Psychiatry August 8th 2023
The preliminary findings suggest a potential new direction for managing chronic pain in PTSD, inviting further research and consideration in the clinical field.
Pain Medicine August 2nd 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS